Solvay S.A.
4.3.2021 08:31:32 CET | Globenewswire | Press release
Participation notification by Blackrock Inc.
Brussels, 4 March 2021, 08:30 CET - According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.) recently sent to Solvay the following transparency notification indicating that it crossed the threshold of 3%. Here is a summary of the move:
| Date on which the threshold was crossed | Voting rights after the transaction | Equivalent financial instruments after the transaction | Total |
| February 25, 2021 | 3.04% | 0.07% | 3.12% |
The latest notification, dated March 1, 2021, contains the following information:
- Reason for the notification: acquisition or disposal of voting securities or voting rights
- Notified by: BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.)
- Date on which the threshold is crossed: February 25, 2021
- Threshold of direct voting rights crossed: 3% upwards
- Denominator: 105,876,416
- Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going above 3%.
Transparency notifications and the full chain of controlled undertakings through which the holding is effectively held is available on the Investor Relations Section of Solvay's website.
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Rocket Lab Corporation28.3.2026 11:39:53 CET | Press release
Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency
Vivoryon Therapeutics N.V.28.3.2026 07:00:00 CET | Press release
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
